Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018
April 16 2018 - 9:00AM
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced in a late-breaking poster session the presentation
of new research from Endocyte’s chimeric antigen receptor T-cell
(CAR T) adaptor molecule (CAM) platform at the AACR Annual Meeting
2018 in Chicago, IL.
“We are pleased to present data that support the utility of our
unique CAR T platform, which potentially enables us to control
cytokine release syndrome (CRS), manage T-cell exhaustion and
address heterogeneity in both solid and liquid tumors through the
administration of multiple CAMs,” said Chris Leamon, vice
president, research and development of Endocyte. “These findings
are critical towards identifying the dosing regimen and confirming
the anti-tumor activity of EC17/CAR T, our folate-targeted
CAM-based therapy, as we look to initiate a phase 1 trial in
osteosarcoma later this year.”
Endocyte’s CAM-based therapies consist of a single universal
autologous CAR T-cell, designed to bind with high affinity to FITC.
This universal CAR T-cell can be specifically directed to cancer
cells through the administration of a bi-specific adaptor molecule
targeted to both FITC and a tumor target, which acts to bridge the
universal CAR T-cell with the cancer cells. This allows for control
of the antigen target through the administration of the CAM, in
contrast to current CAR T-cell therapies, in which the antigen
targets are not controlled.
The data presented at AACR show that EC17 penetrates solid
tumors within minutes and is retained due to high affinity for the
folate receptor (FR), while unbound EC17 rapidly clears from the
blood and receptor-negative tissues. When tested against human
xenografts, EC17/CAR T-cell therapy has shown consistent antitumor
activity with low or no adverse reactions. For translation into
first-in-human testing, clinically relevant dosing regimens were
evaluated using tumor-free and tumor-bearing mice to study CAR
T-cell proliferation, cytokine production and the onset/mitigation
of CRS. Preclinically, EC17/CAR T-cell therapy has demonstrated
meaningful efficacy against some of the more aggressive and
chemo-resistant FR+ tumors of various histology.
Although CRS could be triggered in this study, it could also be
mitigated, or even prevented, using intermittent dosing and/or dose
titration of the EC17 CAM. Under extreme conditions where dose
cessation failed, intravenous sodium fluorescein (NaFl) could be
used as a fast-acting rescue agent to temporarily displace CAR
T-cells from their targets and reverse the CRS.
Website InformationEndocyte
routinely posts important information for investors on its website,
www.endocyte.com, in the “Investors & News” section. Endocyte
uses this website as a means of disclosing material information in
compliance with its disclosure obligations under Regulation
FD. Accordingly, investors should monitor the “Investors &
News” section of Endocyte’s website, in addition to following its
press releases, SEC filings, public conference calls, presentations
and webcasts. The information contained on, or that may be
accessed through, Endocyte’s website is not incorporated by
reference into, and is not a part of, this document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617,
entering phase 3 for metastatic castration resistant prostate
cancer (mCRPC). Endocyte is also advancing its adaptor-controlled
CAR T-cell therapy into the clinic in 2018, where it will be
studied in osteosarcoma. For additional information, please visit
Endocyte's website at www.endocyte.com.
Forward Looking Statements – Legal to
Update
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company's
future development plans including those relating to the completion
of pre-clinical development in preparation for possible future
clinical trials, the anticipated initiation of a registration
trial, and preparation for potential commercialization. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include risks that the company or
independent investigators may experience delays in the initiation
or completion of clinical trials (whether caused by competition,
adverse events, patient enrollment rates, shortage of clinical
trial materials, regulatory issues or other factors); risks that
data from prior clinical trials may not be indicative of subsequent
clinical trial results; risks related to the safety and efficacy of
the company’s product candidates; risks that early stage
pre-clinical data may not be indicative of subsequent data when
expanded to additional pre-clinical models or to subsequent
clinical data; risks that evolving competitive activity and
intellectual property landscape may impair the company's ability to
capture value for the technology; risks that expectations and
estimates turn out to be incorrect, including estimates of the
potential markets for the company’s product candidates, estimates
of the capacity of manufacturing and other facilities required to
support its product candidates, projected cash needs, and expected
future revenues, operations, expenditures and cash position. More
information about the risks and uncertainties faced by Endocyte,
Inc. is contained in the company’s periodic reports filed with the
Securities and Exchange Commission. Endocyte, Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:Stephanie Ascher, Stern
Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2023 to Apr 2024